疫苗板塊拉昇走強 鍾南山稱全球通過疫苗免疫需二到三年
格隆匯5月14日丨疫苗板塊拉昇走強,西藏藥業漲停,沃森生物大漲超8%,康希諾漲超5%,復星醫藥、未名醫藥、康泰生物等跟漲。

昨日,中國工程院院士鍾南山表示,數據顯示目前中國新冠疫苗接種率在23%左右,這遠遠不夠,至少需要達到70%-80%的接種率,這是一個艱鉅的任務。
鍾南山稱,自然感染會造成70%-80%的感染率和5%的死亡率,因此“自然免疫不現實、不科學、不人道。”同時,實現羣體免疫的另一種方式是大規模疫苗接種,這需要2-3年時間的全球協作。在疫苗有效性達到70%的時候,要實現羣體免疫,全球、中國、亞洲以及歐洲接種率需分別達到89.2%、83.3%、80.2%、96.2%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.